VieCuri Medisch Centrum
Welcome,         Profile    Billing    Logout  
 35 Trials 
121 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Wouw, Y van der
LyRICX, NCT03764553: Liposomal iRInotecan, Carboplatin or oXaliplatin for Esophagogastric Cancer

Recruiting
2
320
Europe
Liposomal Irinotecan, Carboplatin, Capecitabine, Xeloda, Oxaliplatin, 5-fluorouracil, Leucovorin
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA), Servier
Esophageal Cancer
07/25
07/26
DRUP, NCT02925234 / 2015-004398-33: The Drug Rediscovery Protocol ( Trial)

Recruiting
2
1550
Europe
Panitumumab, Vectibix, Olaparib, Lynparza, Dabrafenib, Tafinlar, Nilotinib, Tasigna, Trametinib, Mekinist, Erlotinib, Tarceva, Trastuzumab and Pertuzumab (combination treatment), Herceptin + Perjeta, Vemurafenib and Cobimetinib (combination treatment), Zelboraf + Cotellic, Vismodegib, Erivedge, Regorafenib, Stivarga, Nivolumab, Opdivo, Afatinib, Giotrif, Dabrafenib and trametinib, Tafinlar and Mekinist, Ribociclib, Kisqali, Lenvatinib, Lenvima, Pembrolizumab, Keytruda, Durvalumab, MEDI4736, Rucaparib, Rubraca, Axitinib, Inlyta, Palbociclib, Ibrance, Crizotinib, Xalkori, Sunitinib, Sutent, Cabozantinib, Cabometyx, Abemaciclib, Verzenios, Alectinib, Alecensa, Atezolizumab and Bevacizumab, Tecentriq and Avastin, Ipilimumab and nivolumab, Yervoy and Opdivo, Entrectinib, Rozlytrek, Talazoparib, Talzenna, Dacomitinib, Vizimpro, Lorlatinib, Lorviqua, Erdafitinib, Balversa, Alpelisib, Piqray, Niraparib, Zejula, Pemigatinib, Pemazyre, Selpercatinib, Retsevmo, Tepotinib, Tepmetko
The Netherlands Cancer Institute, Amgen, AstraZeneca, Bayer, Bristol-Myers Squibb, Novartis, Roche Pharma AG, Merck Sharp & Dohme LLC, Boehringer Ingelheim, Ipsen, Eisai Inc., Pfizer, Clovis Oncology - Pharma and, Eli Lilly and Company, Janssen, LP, GlaxoSmithKline, Incyte Corporation, Dutch Cancer Society, Stelvio for Life
Cancer, Tumors, Neoplasm, Neoplasia
09/27
12/27
Wouw, A J van der
Triple-B, NCT01898117 / 2013-001484-23: Study;Carboplatin-cyclophosphamide Versus Paclitaxel With or Without Atezolizumab as First-line Treatment in Advanced Triple Negative Breast Cancer

Active, not recruiting
2
304
Europe
Carbo/cyclo, Carboplatin, Cyclophosphamide, Carbo/cyclo + atezolizumab, Atezolizumab, Paclitaxel, Paclitaxel + Atezolizumab
The Netherlands Cancer Institute, Borstkanker Onderzoek Groep, Roche Pharma AG
Breast Cancer
12/24
12/30
SEQUEL-Breast, NCT05392608: SEQUence of Endocrine Therapy in Advanced Luminal Breast Cancer

Recruiting
2
130
Europe
Alpelisib 150 MG Oral Tablet [Piqray], Piqray, Fulvestrant, Faslodex
Borstkanker Onderzoek Groep, Novartis Pharma B.V., BOOG Study Center
Neoplasm, Breast, Congenital, Familial and Genetic Disorders
12/24
03/28
Bouman, Esther
HER2CLIMB-05, NCT05132582 / 2021-002491-39: A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer

Calendar Jan 2025 - Dec 2025: From MOUNTAINEER-02 trial in combination with Herceptin and Cyramza for metastatic HER2+ gastric cancer
Active, not recruiting
3
654
Europe, Canada, Japan, US, RoW
Tucatinib, TUKYSA, ONT-380, ARRY-380, Trastuzumab, Herceptin, Herceptin Hylecta, Pertuzumab, Perjeta, Combination product: Trastuzumab + Pertuzumab, Phesgo, Placebo
Seagen Inc., Merck Sharp & Dohme LLC
HER2 Positive Breast Cancer
05/25
10/27
NCT04842253: HFNC vs LFNC in Patients With AF Undergoing RFCA Under Deep Sedation.

Recruiting
N/A
210
Europe
High flow nasal cannula, High flow nasal oxygen
Maastricht University Medical Center
Deep Sedation, Oxygen Therapy, Radiofrequency Ablation
04/25
05/25
Jeong, Joon
ODYSSEY, NCT04373564: Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years

Recruiting
4
2076
Europe, Canada, US, RoW
Motor Tests, Cognitive Tests, Unenhanced-MRI of the brain, Gadolinium Measurements, Gadoxetate disodium, Eovist, Primovist, BAY86-4873, Gadobenate dimeglumine, MultiHance, Gadodiamide, Omniscan, Gadoterate meglumine, Dotarem, Magnescope, Gadobutrol, BAY86-4875, Gadavist, Gadovist, Gadoteridol, ProHance
Guerbet, Bayer AG (Sponsor), Bracco (Sponsor), GEHC (Sponsor)
Motor Function, Cognitive Function, Contrast Media
12/28
12/28
HER2CLIMB-05, NCT05132582 / 2021-002491-39: A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer

Calendar Jan 2025 - Dec 2025: From MOUNTAINEER-02 trial in combination with Herceptin and Cyramza for metastatic HER2+ gastric cancer
Active, not recruiting
3
654
Europe, Canada, Japan, US, RoW
Tucatinib, TUKYSA, ONT-380, ARRY-380, Trastuzumab, Herceptin, Herceptin Hylecta, Pertuzumab, Perjeta, Combination product: Trastuzumab + Pertuzumab, Phesgo, Placebo
Seagen Inc., Merck Sharp & Dohme LLC
HER2 Positive Breast Cancer
05/25
10/27
CLEAR, NCT03750396: Local Treatment in ER-positive/HER2-negative Oligo-metastatic Breast Cancer

Recruiting
2
110
RoW
Surgical resection, Stereotactic body radiotherapy, SBRT, Radiofrequency ablation, RFA
Gangnam Severance Hospital, Severance Hospital, Samsung Medical Center, Asan Medical Center
Breast Cancer, Recurrent Breast Cancer, Stereotactic Body Radiotherapy, Estrogen Receptor Positive Tumor, Her2-negative Tumor, Surgery
07/21
07/25
NCT04817540: Phase II Trial of Anti-HER2 Treatment in HER2-enriched Early Breast Cancer Identified by PAM50 (HER2E-PAM, PAMILIA Study)

Recruiting
2
59
RoW
Herzuma
Gangnam Severance Hospital
HER2 Enriched Subtype Breast Cancer, Herzuma, PAM50 Study
03/24
03/27
NCT04741737: Repeat Sentinel Lymph Node Biopsy in Ipsilateral Breast Tumor Recurrence

Recruiting
N/A
532
RoW
reSLNB arm
Gangnam Severance Hospital
Mastectomy
01/24
01/29
Sonke, Gabe S
TRAIN-2, NCT01996267: Neoadjuvant Chemotherapy in HER2 Positive Breast Cancer,

Active, not recruiting
3
437
Europe
PTC+Pertuzumab, Paclitaxel; 80 mg/m2; day 1,8, Trastuzumab; 6 mg/kg (loading dose 8 mg/kg); day 1, Carboplatin; AUC=6; day 1, Pertuzumab; 420 mg (loading dose 840 mg); day 1, FEC-T+Pertuzumab, Fluorouracil; 500 mg/m2; day 1, Epirubicine; 90 mg/m2; day 1, Cyclophosphamide 500 mg/m2; day 1, Trastuzumab; 6 mg/kg (loading dose 8 mg/kg)
The Netherlands Cancer Institute, Roche Pharma AG, Borstkanker Onderzoek Groep
Breast Cancer, HER2 Positive
12/18
12/30
Oligo, NCT01646034 / 2012-000838-19: High Dose Chemotherapy in -metastatic Homologous Recombination Deficient Breast Cancer

Active, not recruiting
3
74
Europe
carboplatin, thiotepa, and cyclophosphamide, chemotherapy (docetaxel, doxorubicin, cyclofosfamide, carboplatin, paclitaxel, gemcitabine)
The Netherlands Cancer Institute
Breast Cancer
01/23
10/26
HER2CLIMB-05, NCT05132582 / 2021-002491-39: A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer

Calendar Jan 2025 - Dec 2025: From MOUNTAINEER-02 trial in combination with Herceptin and Cyramza for metastatic HER2+ gastric cancer
Active, not recruiting
3
654
Europe, Canada, Japan, US, RoW
Tucatinib, TUKYSA, ONT-380, ARRY-380, Trastuzumab, Herceptin, Herceptin Hylecta, Pertuzumab, Perjeta, Combination product: Trastuzumab + Pertuzumab, Phesgo, Placebo
Seagen Inc., Merck Sharp & Dohme LLC
HER2 Positive Breast Cancer
05/25
10/27
TRAIN-4, NCT06162559: Neoadjuvant Trastuzumab, Pertuzumab and Tucatinib Without Chemotherapy in HER2-positive Breast Cancer: the Study

Recruiting
1
30
Europe
Tucatinib, Tukysa, Trastuzumab, Herceptin, Pertuzumab, Perjeta
The Netherlands Cancer Institute, Seagen Inc.
Breast Cancer
08/26
05/36
Verkooijen, Lenny HM
PLCRC, NCT02070146: Prospective Data Collection Initiative on Colorectal Cancer

Recruiting
N/A
50000
Europe
Dutch Colorectal Cancer Group
Colorectal Cancer
01/50
01/51
Bool, Coby van de
NCT05335525: Post-market Clinical Investigation of the Angio-Seal™ VIP VCD (ANGIO-SEAL CLOSE)

Recruiting
N/A
230
Europe
Closure of the femoral arterial puncture site
Terumo Europe N.V., Terumo Medical Corporation
Vascular Closure, Endovascular Procedure, Hemostasis, Peripheral Vascular Disease, Femoral Artery
05/23
05/23
Cremolini, Chiara
MOUNTAINEER-03, NCT05253651 / 2021-002672-40: A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer

Recruiting
3
400
Europe, Canada, Japan, US, RoW
tucatinib, TUKYSA, ONT-380, ARRY-380, PF-07265792, trastuzumab, Herceptin, bevacizumab, Avastin, cetuximab, Erbitux, oxaliplatin, leucovorin, levoleucovorin, fluorouracil
Seagen Inc., Merck Sharp & Dohme LLC
Colorectal Neoplasms
08/25
04/28
AZUR-2, NCT05855200: Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer

Recruiting
3
711
Europe, Canada, Japan, US, RoW
Dostarlimab, CAPEOX, FOLFOX
GlaxoSmithKline
Colonic Neoplasms, Neoplasms, Colon
12/28
12/30
COLT, NCT03803436: Improving Outcome of Selected Patients With Non-resectable Hepatic Metastases From Colo-rectal Cancer With Liver Transplantation

Recruiting
2
22
Europe
Liver transplant, Chemotherapy
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Istituto Di Ricerche Farmacologiche Mario Negri, Gruppo Oncologico del Nord-Ovest
Liver Metastases, Colorectal Cancer Metastatic, Liver Neoplasm, Neoplasms
01/24
01/24
C-800-25, NCT05608044: A Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer

Active, not recruiting
2
234
Europe, US, RoW
Botensilimab, AGEN1181, Balstilimab, AGEN2034, Standard of Care
Agenus Inc.
Metastatic Colorectal Cancer
02/25
07/25
AZUR-1, NCT05723562 / 2022-003289-18: A Study of Dostarlimab in Untreated dMMR/MSI-H Locally Advanced Rectal Cancer

Active, not recruiting
2
154
Europe, Canada, Japan, US, RoW
Dostarlimab, JEMPERLI, dostarlimab-gxly, TSR-042, GSK4057190A
GlaxoSmithKline, GlaxoSmithKline Research & Development Ltd
Neoplasms, Rectal
11/26
10/29
C-PRECISE-01, NCT04495621 / 2019-003727-38: MEN1611 With Cetuximab in Metastatic Colorectal Cancer

Completed
1/2
29
Europe, US
MEN1611, Cetuximab
Menarini Group, Menarini Ricerche S.p.A.
Metastatic Colorectal Cancer
01/24
02/24
TriComB, NCT04564898: Trifluridine/Tipiracil in Combination With Capecitabine and Bevacizumab in Metastatic Colorectal Cancer Patients.

Active, not recruiting
1/2
48
Europe
Capecitabine, Bevacizumab, Trifluridine/Tipiracil
Gruppo Oncologico del Nord-Ovest
Colorectal Cancer Metastatic
05/24
05/25
ELVN-002-003, NCT06328738: ELVN-002 with Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer

Recruiting
1
275
Europe, US, RoW
ELVN-002, Trastuzumab, 5-Fluorouracil, Oxaliplatin, Capecitabine, Eribulin, paclitaxel, Leucovorin
Enliven Therapeutics
HER2-positive Breast Cancer, HER2-positive Gastric Cancer, HER2 Positive Solid Tumors, HER2 Amplification, Colorectal Cancer
01/27
07/28
ALFAOMEGA, NCT04120935: Master Observational Trial

Recruiting
N/A
3000
Europe
Observation
IFOM ETS - The AIRC Institute of Molecular Oncology
Colorectal Cancer
07/25
12/25
RATIONAL, NCT05918666: National Register of Actionable Mutations

Recruiting
N/A
3000
Europe
Federation of Italian Cooperative Oncology Groups, Roche Pharma AG, AstraZeneca, Bayer, Bristol-Myers Squibb, Janssen, LP, Takeda, Amgen, Daiichi Sankyo, Inc., Eli Lilly and Company, Novartis, Clinical Research Technology S.r.l.
Solid Tumours in Advanced Stages
10/26
10/26
Wouw, Agnes J van de
HER2CLIMB-05, NCT05132582 / 2021-002491-39: A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer

Calendar Jan 2025 - Dec 2025: From MOUNTAINEER-02 trial in combination with Herceptin and Cyramza for metastatic HER2+ gastric cancer
Active, not recruiting
3
654
Europe, Canada, Japan, US, RoW
Tucatinib, TUKYSA, ONT-380, ARRY-380, Trastuzumab, Herceptin, Herceptin Hylecta, Pertuzumab, Perjeta, Combination product: Trastuzumab + Pertuzumab, Phesgo, Placebo
Seagen Inc., Merck Sharp & Dohme LLC
HER2 Positive Breast Cancer
05/25
10/27
MOUNTAINEER-03, NCT05253651 / 2021-002672-40: A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer

Recruiting
3
400
Europe, Canada, Japan, US, RoW
tucatinib, TUKYSA, ONT-380, ARRY-380, PF-07265792, trastuzumab, Herceptin, bevacizumab, Avastin, cetuximab, Erbitux, oxaliplatin, leucovorin, levoleucovorin, fluorouracil
Seagen Inc., Merck Sharp & Dohme LLC
Colorectal Neoplasms
08/25
04/28
Nishina, Tomohiro
ALTAIR, NCT04457297: Initial Attack on Latent Metastasis Using TAS-102 for ct DNA Identified Colorectal Cancer Patients After Curative Resection

Recruiting
3
240
Japan, RoW
trifluridine and tipiracil, Placebo
National Cancer Center Hospital East, Alpha-A, Inc.
Colorectal Neoplasms, Trifluridine and Tipiracil, Circulating Tumor DNA
05/23
12/23
HERIZON-GEA-01, NCT05152147 / 2021-000296-36: A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers

Recruiting
3
918
Europe, Canada, Japan, RoW
Zanidatamab, ZW25, JZP598, Tislelizumab, Trastuzumab, Herceptin®, Capecitabine, Oxaliplatin, Cisplatin, 5-Fluorouracil
Jazz Pharmaceuticals, BeiGene, Ltd.
Gastric Neoplasms, Gastroesophageal Adenocarcinoma, Esophageal Adenocarcinoma
05/25
05/26
INTEGRATEIIb, NCT04879368 / 2020-004617-12: RegoNivo vs Standard of Care Chemotherapy in AGOC

Active, not recruiting
3
450
Europe, Japan, US, RoW
Regorafenib, Stivarga, Nivolumab, Opdivo, Docetaxel, Taxotere, Paclitaxel, Abraxane, Irinotecan, Camptosar, Trifluridine/Tipracil, Lonsurf
Australasian Gastro-Intestinal Trials Group, Bayer, Bristol-Myers Squibb, University of Sydney, Academic and Community Cancer Research United, Taiwanese Cooperative Oncology Group, Frankfurter Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, National Cancer Center Hospital East, Syneos Health
Gastro-Oesophageal Cancer
06/25
06/26
MOUNTAINEER-03, NCT05253651 / 2021-002672-40: A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer

Recruiting
3
400
Europe, Canada, Japan, US, RoW
tucatinib, TUKYSA, ONT-380, ARRY-380, PF-07265792, trastuzumab, Herceptin, bevacizumab, Avastin, cetuximab, Erbitux, oxaliplatin, leucovorin, levoleucovorin, fluorouracil
Seagen Inc., Merck Sharp & Dohme LLC
Colorectal Neoplasms
08/25
04/28
Peters, NAJB
CrEATE, NCT06434896: Circulating Tumor DNA Based Adjuvant Chemotherapy in Stage II Colon Cancer Patients: the MEDOCC- Trial

Recruiting
N/A
1320
Europe
ctDNA analysis after surgery
UMC Utrecht, Personal Genome Diagnostics (PGDx), The Netherlands Cancer Institute
Circulating Tumor DNA, Recurrence, Colon Cancer Stage II
03/35
03/35
PLCRC, NCT02070146: Prospective Data Collection Initiative on Colorectal Cancer

Recruiting
N/A
50000
Europe
Dutch Colorectal Cancer Group
Colorectal Cancer
01/50
01/51
Antonuzzo, Lorenzo
JS001-027-III-HCC, NCT04523493 / 2020-004437-20: Phase III Study of Toripalimab（JS001） Combined With Lenvatinib for Advanced HCC

Active, not recruiting
3
530
Europe, RoW
Toripalimab combined with Lenvatinib, Placebo combined with Lenvatinib
Shanghai Junshi Bioscience Co., Ltd., Shanghai Junshi Biosciences Co., Ltd
Advanced Hepatocellular Carcinoma (HCC)
05/25
09/26
PANOVA-3, NCT03377491: Effect of Tumor Treating Fields (TTFields, 150 kHz) as Front-Line Treatment of Locally-advanced Pancreatic Adenocarcinoma Concomitant With Gemcitabine and Nab-paclitaxel

Completed
3
571
Europe, Canada, US, RoW
NovoTTF-200T, TTFields, Gemcitabine, nab paclitaxel
NovoCure Ltd.
Pancreas Adenocarcinoma
10/24
10/24
MOUNTAINEER-03, NCT05253651 / 2021-002672-40: A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer

Recruiting
3
400
Europe, Canada, Japan, US, RoW
tucatinib, TUKYSA, ONT-380, ARRY-380, PF-07265792, trastuzumab, Herceptin, bevacizumab, Avastin, cetuximab, Erbitux, oxaliplatin, leucovorin, levoleucovorin, fluorouracil
Seagen Inc., Merck Sharp & Dohme LLC
Colorectal Neoplasms
08/25
04/28
NCT06095583: Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC)

Recruiting
3
756
Europe, US, RoW
Tifcemalimab injection, toripalimab injection, Placebo for Tifcemalimab, Placebo for toripalimab
Shanghai Junshi Bioscience Co., Ltd.
Limited-stage Small Cell Lung Cancer (LS-SCLC)
07/27
07/29
SENECA, NCT03387592 / 2016-000767-17: CAPTEM or FOLFIRI as SEcond-line Therapy in NEuroendocrine CArcinomas

Recruiting
2
112
Europe
CPT-11, Calcio levofolinate, 5-Fluorouracil, Capecitabine, Temozolomide
Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori
Neuroendocrine Carcinoma
01/22
01/22
DUPLE, NCT06418087: Durvalumab With Carboplatin and Etoposide Chemotherapy in Pulmonary Large-cell Neuroendocrine Carcinoma (LCNEC)

Recruiting
2
49
Europe
Durvalumab 50 MG/1 ML Intravenous Solution [IMFINZI], Carboplatino AHCL 10 mg/ml Concentrate for solution for infusion, Etoposide 20 mg/ml Concentrate for solution for infusion
Gruppo Oncologico Italiano di Ricerca Clinica
Pulmonary Large-cell Neuroendocrine Carcinoma
12/26
12/26
NCT02687958: Study of Everolimus as Maintenance Therapy for Metastatic NEC With Pulmonary or Gastroenteropancreatic Origin

Active, not recruiting
2
30
Europe
Everolimus, Afinitor
Gruppo Oncologico Italiano di Ricerca Clinica, Novartis
Neuroendocrine Carcinoma
12/22
12/23
NCT04579679 / 2020-006118-19: Open-Label Surufatinib in European Patients With NET

Active, not recruiting
2
78
Europe, US
Surufatinib, HMPL-012, sulfatinib
Hutchmed
Neuroendocrine Tumours, Neuroendocrine Tumour of the Lung, Small Intestinal NET
09/24
09/24
ALK-PPL, NCT06378892: A Study to Evaluate the Combination of Platinum-pemetrexed Based Chemotherapy Plus Lorlatinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) With Exclusively Extracranial Disease Progression on Lorlatinib

Recruiting
2
45
Europe
Lorlatinib
Centro di Riferimento Oncologico - Aviano
Non Small Cell Lung Cancer Metastatic, ALK Gene Mutation
05/28
05/28
SGNLVA-005, NCT04032704 / 2019-001946-17: A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors

Terminated
2
205
Europe, US, RoW
ladiratuzumab vedotin, SGN-LIV1A, pembrolizumab, Keytruda
Seagen Inc., Merck Sharp & Dohme LLC
Small Cell Lung Cancer, Non-small Cell Lung Cancer, Squamous, Non-small Cell Lung Cancer, Non-squamous, Head and Neck Squamous Cell Carcinoma, Esophageal Squamous Cell Carcinoma, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Prostate Cancer, Melanoma
11/23
11/23
JAVELIN Bladder Medley, NCT05327530: A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in Locally Advanced or Metastatic Urothelial Carcinoma

Active, not recruiting
2
256
Europe, Canada, US, RoW
Avelumab, MSB0010718C, Sacituzumab Govitecan, IMMU-132, Trodelvy™, GS-0132, M6223, NKTR-255
EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany; Gilead Sciences; Nektar Therapeutics
Locally Advanced or Metastatic Urothelial Carcinoma
01/25
01/25
CAVE 2, NCT05291156: CAVE-2 GOIM Study: a Clinical Study of the Combination of Avelumab Plus Cetuximab as Rechallenge Strategy

Recruiting
2
173
Europe
Cetuximab, Erbitux, Avelumab, Bavencio
University of Campania "Luigi Vanvitelli"
Metastatic Colorectal Cancer
07/25
07/25
AxIn, NCT05817903 / 2022-001150-35: Axitinib Intensification Plus Nivolumab or Nivolumab Alone After Nivolumab Plus Ipilimumab in mRCC Patients

Recruiting
2
118
Europe
Axitinib, Inlyta, Nivolumab
Consorzio Oncotech, Pfizer
Metastatic Renal Cell Carcinoma
04/26
04/27
REZILIENT1, NCT04036682: A Phase 1/2 Trial of CLN-081 in Patients with Non-Small Cell Lung Cancer

Checkmark Data from a trial for NSCLC
Jan 2022 - Jan 2022: Data from a trial for NSCLC
Active, not recruiting
1/2
284
Europe, Japan, US, RoW
CLN-081, TAS6417; zipalertinib
Cullinan Therapeutics Inc.
Non Small Cell Lung Cancer, EGFR Exon 20 Mutation
12/24
12/24
Argonaut, NCT05480865: SHP2 Inhibitor BBP-398 in Combination With Sotorasib in Patients With Advanced Solid Tumors and a KRAS-G12C Mutation

Terminated
1
28
Europe, RoW
BBP-398, sotorasib
Navire Pharma Inc., a BridgeBio company, Amgen
Solid Tumor, Adult, Metastatic Solid Tumor, Metastatic NSCLC, Non Small Cell Lung Cancer
08/24
08/24
Key-Early, NCT06467383: A Study to Describe the Diagnostic and Therapeutic Path of Patients with NSCLC in Early Stage and Locally Advanced

Recruiting
N/A
600
Europe
MSD Italia S.r.l., YGHEA, CRO Division of Ecol Studio spa
Non-small Cell Lung Cancer, NSCLC, NSCLC, Stage III, NSCLC, Stage I
06/25
06/25
RATIONAL, NCT05918666: National Register of Actionable Mutations

Recruiting
N/A
3000
Europe
Federation of Italian Cooperative Oncology Groups, Roche Pharma AG, AstraZeneca, Bayer, Bristol-Myers Squibb, Janssen, LP, Takeda, Amgen, Daiichi Sankyo, Inc., Eli Lilly and Company, Novartis, Clinical Research Technology S.r.l.
Solid Tumours in Advanced Stages
10/26
10/26
Vogelaar, FJ
PLCRC, NCT02070146: Prospective Data Collection Initiative on Colorectal Cancer

Recruiting
N/A
50000
Europe
Dutch Colorectal Cancer Group
Colorectal Cancer
01/50
01/51
Pillinger, Michael
CLOAK, NCT03913442: Colchicine for the Treatment of Osteoarthritis of the Knee

Completed
4
120
US
Colchicine 0.8 mg or 0.6 mg orally once daily, Placebo oral capsule
NYU Langone Health
Osteoarthritis, Osteo Arthritis Knee
01/24
01/24
TRUST, NCT04875702: Treat-to-Target Serum Urate Versus Treat-to-Avoid Symptoms in Gout

Recruiting
4
650
US
Allopurinol, Aloprim, Zyloprim, Naproxen 250 MG, Prophylaxis, Colchicine 0.6 mg, Colchicine 1.2 mg, Flare, Naproxen 500 Mg, Prednisone 40 mg
Massachusetts General Hospital, National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Gout
09/28
10/28
NCT05658575 / 2019-002717-19: Study of Dapansutrile Tablets in Subjects With an Acute Gout Flare

Recruiting
2/3
300
Europe, US, RoW
Dapansutrile, OLT1177, Placebo Tablet
Olatec Therapeutics LLC, Olatec Therapeutics LLC
Acute Gout Flare, Gout Attack, Gout Flare, Gouty Arthritis, Gout, Arthritis, Joint Pain
09/25
10/25
Wouw, AJ Van De
NCT02301286: A Trial of Aspirin on Recurrence and Survival in Colon Cancer Patients

Active, not recruiting
3
770
Europe
Acetylsalicylic acid, Aspirin, Placebo Acetylsalicylic acid, Placebo
Leiden University, Stichting voor Patienten met Kanker aan het Spijsverteringskanaal (SPKS), Dutch Colorectal Cancer Group, Stichting Geriatrische Oncologie Nederland (GeriOnNe), Fonds NutsOhra, Innovatiefonds Zorgverzekeraars
Colon Cancer, Adjuvant Therapy
12/27
12/27
DIRECT-2, NCT05503108: Fasting Mimicking Diet Program to ImpRovE ChemoTherapy in Hormone Receptor Postive (HR+), HER2- Breast Cancer

Suspended
3
10
Europe
Fasting Mimicking diet program, Xentigen™
Leiden University Medical Center, The Netherlands Cancer Institute, Borstkanker Onderzoek Groep, Comprehensive Cancer Centre The Netherlands, Koningin Wilhelmina Fonds, World Cancer Research Fund International, L-Nutra Inc
Fasting Mimicking Diet, HER2-negative Breast Cancer, Hormone Receptor-positive Breast Cancer, Pathological Complete Response, Objective Response Rate, Neoadjuvant Chemotherapy
01/24
01/24
Vestjens, H
CAIRO5, NCT02162563 / 2013-005435-24: Treatment Strategies in Colorectal Cancer Patients With Initially Unresectable Liver-only Metastases

Recruiting
3
564
Europe
FOLFOX/ FOLFIRI with bevacizumab, - bevacizumab, - irinotecan, - leucovorin, - 5-fluorouracil, - oxaliplatin, FOLFOXIRI with bevacizumab, FOLFOX/ FOLFIRI with panitumumab, - panitumumab
Dutch Colorectal Cancer Group
Colorectal Cancer, Liver Metastases
08/22
07/25
NCT05646615: Experiences and Health-related Quality of Life of Informal Caregivers of Dialysis Patients

Completed
N/A
202
Europe
B.C. van Jaarsveld, Admiraal de Ruyter Hospital, Alrijne Hospital, Amphia Hospital, St. Antonius Hospital, Canisius-Wilhelmina Hospital, Catharina Ziekenhuis Eindhoven, Deventer Ziekenhuis, Dialysis Center Beverwijk, Tergooi Hospital, Diapriva Dialysis Center, Amsterdam, Elkerliek Hospital, Flevoziekenhuis, Gelre Hospitals, Groene Hart Ziekenhuis, Haga Hospital, Isala, Laurentius Hospital, Maasstad Hospital, Maxima Medical Center, Noordwest Ziekenhuisgroep, OLVG Oost, OLVG West, Radboud University Medical Center, Reinier de Graaf Groep, Rijnstate Hospital, Saxenburgh Group, Slingeland Hospital, UMC Utrecht, VieCuri Medical Centre, Amsterdam UMC, Bernhoven Hospital, ZorgSaam, Jessa Hospital
Peritoneal Dialysis, Hemodialysis, Home, Hemodialysis, Quality of Life, Informal Caregivers, Family Caregivers, Renal Replacement Therapy, Kidney Failure, Chronic, Patient Reported Outcome Measures
12/23
12/23
Boon, Eline
HER2CLIMB-05, NCT05132582 / 2021-002491-39: A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer

Calendar Jan 2025 - Dec 2025: From MOUNTAINEER-02 trial in combination with Herceptin and Cyramza for metastatic HER2+ gastric cancer
Active, not recruiting
3
654
Europe, Canada, Japan, US, RoW
Tucatinib, TUKYSA, ONT-380, ARRY-380, Trastuzumab, Herceptin, Herceptin Hylecta, Pertuzumab, Perjeta, Combination product: Trastuzumab + Pertuzumab, Phesgo, Placebo
Seagen Inc., Merck Sharp & Dohme LLC
HER2 Positive Breast Cancer
05/25
10/27
MOUNTAINEER-03, NCT05253651 / 2021-002672-40: A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer

Recruiting
3
400
Europe, Canada, Japan, US, RoW
tucatinib, TUKYSA, ONT-380, ARRY-380, PF-07265792, trastuzumab, Herceptin, bevacizumab, Avastin, cetuximab, Erbitux, oxaliplatin, leucovorin, levoleucovorin, fluorouracil
Seagen Inc., Merck Sharp & Dohme LLC
Colorectal Neoplasms
08/25
04/28
Yamaguchi, Kensei
ALTAIR, NCT04457297: Initial Attack on Latent Metastasis Using TAS-102 for ct DNA Identified Colorectal Cancer Patients After Curative Resection

Recruiting
3
240
Japan, RoW
trifluridine and tipiracil, Placebo
National Cancer Center Hospital East, Alpha-A, Inc.
Colorectal Neoplasms, Trifluridine and Tipiracil, Circulating Tumor DNA
05/23
12/23
HERIZON-GEA-01, NCT05152147 / 2021-000296-36: A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers

Recruiting
3
918
Europe, Canada, Japan, RoW
Zanidatamab, ZW25, JZP598, Tislelizumab, Trastuzumab, Herceptin®, Capecitabine, Oxaliplatin, Cisplatin, 5-Fluorouracil
Jazz Pharmaceuticals, BeiGene, Ltd.
Gastric Neoplasms, Gastroesophageal Adenocarcinoma, Esophageal Adenocarcinoma
05/25
05/26
MOUNTAINEER-03, NCT05253651 / 2021-002672-40: A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer

Recruiting
3
400
Europe, Canada, Japan, US, RoW
tucatinib, TUKYSA, ONT-380, ARRY-380, PF-07265792, trastuzumab, Herceptin, bevacizumab, Avastin, cetuximab, Erbitux, oxaliplatin, leucovorin, levoleucovorin, fluorouracil
Seagen Inc., Merck Sharp & Dohme LLC
Colorectal Neoplasms
08/25
04/28
SGNTUC 024, NCT04430738: Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers

Active, not recruiting
1/2
40
Japan, US
tucatinib, TUKYSA, trastuzumab, oxaliplatin, leucovorin, fluorouracil, capecitabine, pembrolizumab, KEYTRUDA
Seagen Inc.
Colorectal Carcinoma, Gastric Adenocarcinoma, GEJ Adenocarcinoma, Esophageal Adenocarcinoma, Cholangiocarcinoma, Gallbladder Carcinoma
07/24
10/25
PROCEADE-CRC-01, NCT05464030: Anti-CEACAM5 ADC M9140 in Advanced Solid Tumors

Recruiting
1
200
Europe, Canada, Japan, US, RoW
M9140, Precemtabart tocentecan, Bevacizumab, Capecitabine, 5-fluorouracil (5-FU), Folinic acid
EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany
Colorectal Cancer
02/26
02/26
Lorenzo, Jose Juan Ponce
HER2CLIMB-05, NCT05132582 / 2021-002491-39: A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer

Calendar Jan 2025 - Dec 2025: From MOUNTAINEER-02 trial in combination with Herceptin and Cyramza for metastatic HER2+ gastric cancer
Active, not recruiting
3
654
Europe, Canada, Japan, US, RoW
Tucatinib, TUKYSA, ONT-380, ARRY-380, Trastuzumab, Herceptin, Herceptin Hylecta, Pertuzumab, Perjeta, Combination product: Trastuzumab + Pertuzumab, Phesgo, Placebo
Seagen Inc., Merck Sharp & Dohme LLC
HER2 Positive Breast Cancer
05/25
10/27
ADELA, NCT06382948: Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i.

Recruiting
3
240
Europe
Everolimus, Zortress, Votubia, RAD001, Certican, Afinitor, Elacestrant, ER-306323, RAD1901, Selective estrogen receptor degrader/selective estrogen receptor modulator (SERD/SERM) RAD1901, Placebo, Auxiliary Medicinal Product - Dexamethasone, Auxiliary Medicinal Product - Luteinizing hormone-releasing hormone (LHRH) analogues
MedSIR, Stemline Therapeutics, Inc.
Advanced Breast Cancer, ER-positive Breast Cancer, HER2-negative Breast Cancer, ESR1 Gene Mutation
09/27
04/28
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

Recruiting
3
6000
Europe, Canada, Japan, US, RoW
Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane
Eli Lilly and Company
Breast Neoplasms
10/27
03/32
DEMETHER, NCT06172127: PHESGO Maintenance After T-DXd Short Induction for HER2+ Unresectable Locally Recurrent or Metastatic Breast Cancer

Recruiting
2
165
Europe, US
Trastuzumab deruxtecan, T-DXd, Phesgo 1,200 MG / 600 MG / 30,000 UNT Per 15 ML Injection, PHESGO, Pertuzumab-Trastuzumab FDC SC, Phesgo 600 MG / 600 MG / 20,000 UNT in 10 mL Injection
MedSIR, Hoffmann-La Roche
HER2-positive Breast Cancer
11/26
05/29
EMPRESS, NCT05659563: Preoperative Window Opportunity Study With Giredestrant or Tamoxifen in Premenopausal Women With ER+/HER2[-] & Ki67≥10%

Completed
2
92
Europe
Giredestrant, GDC-9545, Tamoxifen, Nolvadex® or Soltamox®
MedSIR
Breast Cancer, Breast Cancer, Early-Onset
01/25
01/25
MiRaDoR, NCT05708235: A PoC Study to Evaluate Treatments' Efficacy by Monitoring MRD Using ctDNA in HR-positive/HER2-negative EBC Population

Active, not recruiting
2
1260
Europe
Giredestrant, GDC-9545, Abemaciclib, LY2835219, Inavolisib, GDC-0077
MedSIR
Breast Cancer
12/28
12/28
ARCTIC-2, NCT05542082: Pilot Study of the CHILLS Cryotherapy System for the Treatment of OSA

Active, not recruiting
N/A
50
RoW
CHILLS Procedure
Cryosa, Inc.
Obstructive Sleep Apnea of Adult
12/23
04/27
Hickey, Eve
NCT05658575 / 2019-002717-19: Study of Dapansutrile Tablets in Subjects With an Acute Gout Flare

Recruiting
2/3
300
Europe, US, RoW
Dapansutrile, OLT1177, Placebo Tablet
Olatec Therapeutics LLC, Olatec Therapeutics LLC
Acute Gout Flare, Gout Attack, Gout Flare, Gouty Arthritis, Gout, Arthritis, Joint Pain
09/25
10/25
Wouw, Yes J van de
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

Recruiting
3
6000
Europe, Canada, Japan, US, RoW
Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane
Eli Lilly and Company
Breast Neoplasms
10/27
03/32
CRITICS-II, NCT02931890 / 2015-004627-31: Multicentric Randomised Trial for Resectable Gastric Cancer

Active, not recruiting
2
207
Europe
Docetaxel, Taxotere, Oxaliplatin, Eloxatin, Capecitabine, Xeloda, gastrectomy, radiotherapy of gastric cancer, Paclitaxel, Carboplatin
The Netherlands Cancer Institute
Gastric Cancer
04/25
03/29
Khanna, Puja
NCT05658575 / 2019-002717-19: Study of Dapansutrile Tablets in Subjects With an Acute Gout Flare

Recruiting
2/3
300
Europe, US, RoW
Dapansutrile, OLT1177, Placebo Tablet
Olatec Therapeutics LLC, Olatec Therapeutics LLC
Acute Gout Flare, Gout Attack, Gout Flare, Gouty Arthritis, Gout, Arthritis, Joint Pain
09/25
10/25
NCT03773471: A Multi-Center Clinical Trial to Determine the Impact of a Mobile Health Application on Rheumatoid Arthritis Shared Decision Making

Completed
N/A
69
US
Mobile Health App
Mayo Clinic
Rheumatoid Arthritis
06/23
06/23
Sunakawa, Yu
ALTAIR, NCT04457297: Initial Attack on Latent Metastasis Using TAS-102 for ct DNA Identified Colorectal Cancer Patients After Curative Resection

Recruiting
3
240
Japan, RoW
trifluridine and tipiracil, Placebo
National Cancer Center Hospital East, Alpha-A, Inc.
Colorectal Neoplasms, Trifluridine and Tipiracil, Circulating Tumor DNA
05/23
12/23
MOUNTAINEER-03, NCT05253651 / 2021-002672-40: A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer

Recruiting
3
400
Europe, Canada, Japan, US, RoW
tucatinib, TUKYSA, ONT-380, ARRY-380, PF-07265792, trastuzumab, Herceptin, bevacizumab, Avastin, cetuximab, Erbitux, oxaliplatin, leucovorin, levoleucovorin, fluorouracil
Seagen Inc., Merck Sharp & Dohme LLC
Colorectal Neoplasms
08/25
04/28
AZUR-2, NCT05855200: Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer

Recruiting
3
711
Europe, Canada, Japan, US, RoW
Dostarlimab, CAPEOX, FOLFOX
GlaxoSmithKline
Colonic Neoplasms, Neoplasms, Colon
12/28
12/30
eNRGy, NCT02912949 / 2014-003277-42: A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion

Active, not recruiting
2
250
Europe, Canada, Japan, US, RoW
zenocutuzumab (MCLA-128), bispecific, MCLA-128
Merus N.V.
Solid Tumours Harboring NRG1 Fusion, NSCLC Harboring NRG1 Fusion, Pancreatic Cancer Harboring NRG1 Fusion, NRG1 Fusion
12/26
12/26
SGNTUC-019, NCT04579380 / 2020-004873-29: Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations

Active, not recruiting
2
217
Europe, Japan, US, RoW
tucatinib, TUKYSA, ARRY-380, ONT-380, trastuzumab, Herceptin, fulvestrant, Faslodex
Seagen Inc., Seagen, Inc.
Uterine Neoplasms, Uterine Cervical Neoplasms, Biliary Tract Neoplasms, Urologic Neoplasms, Carcinoma, Non-Small-Cell Lung, HER2 Mutations Breast Neoplasms
11/23
05/25
SGNTUC 024, NCT04430738: Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers

Active, not recruiting
1/2
40
Japan, US
tucatinib, TUKYSA, trastuzumab, oxaliplatin, leucovorin, fluorouracil, capecitabine, pembrolizumab, KEYTRUDA
Seagen Inc.
Colorectal Carcinoma, Gastric Adenocarcinoma, GEJ Adenocarcinoma, Esophageal Adenocarcinoma, Cholangiocarcinoma, Gallbladder Carcinoma
07/24
10/25
Takashima, Atsuo
ALTAIR, NCT04457297: Initial Attack on Latent Metastasis Using TAS-102 for ct DNA Identified Colorectal Cancer Patients After Curative Resection

Recruiting
3
240
Japan, RoW
trifluridine and tipiracil, Placebo
National Cancer Center Hospital East, Alpha-A, Inc.
Colorectal Neoplasms, Trifluridine and Tipiracil, Circulating Tumor DNA
05/23
12/23
MOUNTAINEER-03, NCT05253651 / 2021-002672-40: A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer

Recruiting
3
400
Europe, Canada, Japan, US, RoW
tucatinib, TUKYSA, ONT-380, ARRY-380, PF-07265792, trastuzumab, Herceptin, bevacizumab, Avastin, cetuximab, Erbitux, oxaliplatin, leucovorin, levoleucovorin, fluorouracil
Seagen Inc., Merck Sharp & Dohme LLC
Colorectal Neoplasms
08/25
04/28
AZUR-2, NCT05855200: Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer

Recruiting
3
711
Europe, Canada, Japan, US, RoW
Dostarlimab, CAPEOX, FOLFOX
GlaxoSmithKline
Colonic Neoplasms, Neoplasms, Colon
12/28
12/30
Remkes, W
CELEBRATE, NCT04825743 / 2020-003320-16: A Phase 3 Study of Zalunfiban in Subjects With ST-elevation MI

Recruiting
3
2499
Europe, Canada, RoW
zalunfiban, RUC-4, Placebo
CeleCor Therapeutics, CeleCor Therapeutics, Inc.
ST-elevation Myocardial Infarction (STEMI)
12/24
12/24
SLIM, NCT03562572: FFR Driven Complete Revascularization Versus Usual Care in NSTEMI Patients and Multivessel Disease

Recruiting
N/A
476
Europe, RoW
Ischemia driven revascularization, Usual care group
Zuyderland Medisch Centrum, Maastricht University Medical Center, Radboud University Medical Center, Jeroen Bosch Ziekenhuis, VieCuri Medical Centre, Gottsegen György Országos Kardiológiai Intézet, Bács-Kiskun County Teaching Hospital, Brno University Hospital, Szeged University
Coronary Artery Disease, NSTEMI - Non-ST Segment Elevation MI, Fractional Flow Reserve, Myocardial, Myocardial Revascularization, Percutaneous Coronary Intervention
12/25
01/28
Esaki, Taito
INTEGRATEIIb, NCT04879368 / 2020-004617-12: RegoNivo vs Standard of Care Chemotherapy in AGOC

Active, not recruiting
3
450
Europe, Japan, US, RoW
Regorafenib, Stivarga, Nivolumab, Opdivo, Docetaxel, Taxotere, Paclitaxel, Abraxane, Irinotecan, Camptosar, Trifluridine/Tipracil, Lonsurf
Australasian Gastro-Intestinal Trials Group, Bayer, Bristol-Myers Squibb, University of Sydney, Academic and Community Cancer Research United, Taiwanese Cooperative Oncology Group, Frankfurter Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, National Cancer Center Hospital East, Syneos Health
Gastro-Oesophageal Cancer
06/25
06/26
MOUNTAINEER-03, NCT05253651 / 2021-002672-40: A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer

Recruiting
3
400
Europe, Canada, Japan, US, RoW
tucatinib, TUKYSA, ONT-380, ARRY-380, PF-07265792, trastuzumab, Herceptin, bevacizumab, Avastin, cetuximab, Erbitux, oxaliplatin, leucovorin, levoleucovorin, fluorouracil
Seagen Inc., Merck Sharp & Dohme LLC
Colorectal Neoplasms
08/25
04/28
Davidis, MA
DRUP, NCT02925234 / 2015-004398-33: The Drug Rediscovery Protocol ( Trial)

Recruiting
2
1550
Europe
Panitumumab, Vectibix, Olaparib, Lynparza, Dabrafenib, Tafinlar, Nilotinib, Tasigna, Trametinib, Mekinist, Erlotinib, Tarceva, Trastuzumab and Pertuzumab (combination treatment), Herceptin + Perjeta, Vemurafenib and Cobimetinib (combination treatment), Zelboraf + Cotellic, Vismodegib, Erivedge, Regorafenib, Stivarga, Nivolumab, Opdivo, Afatinib, Giotrif, Dabrafenib and trametinib, Tafinlar and Mekinist, Ribociclib, Kisqali, Lenvatinib, Lenvima, Pembrolizumab, Keytruda, Durvalumab, MEDI4736, Rucaparib, Rubraca, Axitinib, Inlyta, Palbociclib, Ibrance, Crizotinib, Xalkori, Sunitinib, Sutent, Cabozantinib, Cabometyx, Abemaciclib, Verzenios, Alectinib, Alecensa, Atezolizumab and Bevacizumab, Tecentriq and Avastin, Ipilimumab and nivolumab, Yervoy and Opdivo, Entrectinib, Rozlytrek, Talazoparib, Talzenna, Dacomitinib, Vizimpro, Lorlatinib, Lorviqua, Erdafitinib, Balversa, Alpelisib, Piqray, Niraparib, Zejula, Pemigatinib, Pemazyre, Selpercatinib, Retsevmo, Tepotinib, Tepmetko
The Netherlands Cancer Institute, Amgen, AstraZeneca, Bayer, Bristol-Myers Squibb, Novartis, Roche Pharma AG, Merck Sharp & Dohme LLC, Boehringer Ingelheim, Ipsen, Eisai Inc., Pfizer, Clovis Oncology - Pharma and, Eli Lilly and Company, Janssen, LP, GlaxoSmithKline, Incyte Corporation, Dutch Cancer Society, Stelvio for Life
Cancer, Tumors, Neoplasm, Neoplasia
09/27
12/27
CrEATE, NCT06434896: Circulating Tumor DNA Based Adjuvant Chemotherapy in Stage II Colon Cancer Patients: the MEDOCC- Trial

Recruiting
N/A
1320
Europe
ctDNA analysis after surgery
UMC Utrecht, Personal Genome Diagnostics (PGDx), The Netherlands Cancer Institute
Circulating Tumor DNA, Recurrence, Colon Cancer Stage II
03/35
03/35
PLCRC, NCT02070146: Prospective Data Collection Initiative on Colorectal Cancer

Recruiting
N/A
50000
Europe
Dutch Colorectal Cancer Group
Colorectal Cancer
01/50
01/51
Santabarbara, Giuseppe
MOUNTAINEER-03, NCT05253651 / 2021-002672-40: A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer

Recruiting
3
400
Europe, Canada, Japan, US, RoW
tucatinib, TUKYSA, ONT-380, ARRY-380, PF-07265792, trastuzumab, Herceptin, bevacizumab, Avastin, cetuximab, Erbitux, oxaliplatin, leucovorin, levoleucovorin, fluorouracil
Seagen Inc., Merck Sharp & Dohme LLC
Colorectal Neoplasms
08/25
04/28
CAVE 2, NCT05291156: CAVE-2 GOIM Study: a Clinical Study of the Combination of Avelumab Plus Cetuximab as Rechallenge Strategy

Recruiting
2
173
Europe
Cetuximab, Erbitux, Avelumab, Bavencio
University of Campania "Luigi Vanvitelli"
Metastatic Colorectal Cancer
07/25
07/25
Arnoldussen, Carsten
NCT05335525: Post-market Clinical Investigation of the Angio-Seal™ VIP VCD (ANGIO-SEAL CLOSE)

Recruiting
N/A
230
Europe
Closure of the femoral arterial puncture site
Terumo Europe N.V., Terumo Medical Corporation
Vascular Closure, Endovascular Procedure, Hemostasis, Peripheral Vascular Disease, Femoral Artery
05/23
05/23
Laar, Rafli van der
PRedICT-TOPIC, NCT05405270: Predicting Response In Cervical Intraepithelial Neoplasia to Topical Imiquimod Treatment

Recruiting
N/A
410
Europe
Imiquimod, Aldara, 3x vaginal swab for microbiome analysis, Expectative management, 2x vaginal swab for microbiome analysis
Catharina Ziekenhuis Eindhoven, ZonMw: The Netherlands Organisation for Health Research and Development, Stichting Olijf: Dutch patient association for women with gynaecological cancer, Leids Universitair Medisch Centrum: Department of Medical Oncology and Department of Pathology, Maastricht Universitair Medisch Centrum: Department of Gynaecology and Department of Pathology, Erasmus Medisch Centrum: Department of Gynaecology, Radboud Medisch Centrum: Department of Gynaecology
Cervical High Grade Squamous Intraepithelial Lesion, Cervical Intraepithelial Neoplasia Grade 2/3, CIN 2/3, Cervical Intraepithelial Neoplasia
12/24
12/26
Hamming, Lisanne
EMBER-3, NCT04975308 / 2021-000079-35: A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer

Active, not recruiting
3
866
Europe, Japan, US, RoW
Imlunestrant, LY3484356, Exemestane, Fulvestrant, Abemaciclib, LY2835219
Eli Lilly and Company, Eli Lilly and Company
Breast Neoplasms, Neoplasm Metastasis
06/24
08/27
 

Download Options